Premium
Treatment of Grass Pollen‐Induced Hay Fever with Intranasal Budesonide
Author(s) -
Steensen H.,
Lindqvist N.
Publication year - 1981
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/j.1398-9995.1981.tb01570.x
Subject(s) - budesonide , microgram , placebo , nasal administration , hay fever , glucocorticoid , medicine , corticosteroid , anesthesia , asthma , pharmacology , chemistry , biochemistry , alternative medicine , pathology , in vitro
The clinical effects of intranasal budesonide (16α, 17α (22 R,S) propylmethylenedioxypre‐gana‐1‐4‐diene‐11β 21 diol‐3, 20 dione)) ‐ a new non‐halogenated glucocorticoid ‐ were evaluated in a double‐blind comparison with placebo, in patients with pronounced hay fever. Aerosolized budesonide, using a daily dosage of either 400 μg or 200 μg, showed a highly significant reduction in the nasal symptoms as compared with placebo. No significant difference could be demonstrated between the effects of 400 μg and 200 μg per day, suggesting that the lower dosage is adequate. No significant effect on the eye symptoms and no fall in plasma cortisol values were observed with either dosage. Only mild side effects were reported.